Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Sponsor
University Health Network, Toronto
Study ID
NCT02472717
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
  • Placebo — OTHER
    Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm

Study Details

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.

Key Dates

Start date
May 31, 2015
Status verified
Jun 2015
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Interventional arm
    liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
  • Placebo Comparator: Placebo arm
    Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm

Primary Outcome Measure

The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo [ Time Frame: Baseline to 12 weeks, liraglutide compared to placebo ]

Related Studies